MESO
Mesoblast LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.97B
P/E Ratio
—
EPS
$-0.74
Beta
0.82
52W High
$21.50
52W Low
$9.88
50-Day MA
$15.37
200-Day MA
$16.28
Dividend Yield
—
Profit Margin
-144.30%
Forward P/E
454.55
PEG Ratio
0.00
About Mesoblast Ltd
Mesoblast Limited, a biopharmaceutical company, develops and markets allogeneic cellular drugs. The company is headquartered in Melbourne, Australia.
Fundamentals
| Revenue (TTM) | $65.38M |
| Gross Profit (TTM) | $-23.23M |
| EBITDA | $-64.34M |
| Operating Margin | -55.20% |
| Return on Equity | -18.20% |
| Return on Assets | -6.16% |
| Revenue/Share (TTM) | $0.51 |
| Book Value | $4.46 |
| Price-to-Book | 3.42 |
| Price-to-Sales (TTM) | 30.09 |
| EV/Revenue | 30.65 |
| EV/EBITDA | -6.55 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1527.00% |
| Shares Outstanding | $129.28M |
| Float | $819.92M |
| % Insiders | 5.05% |
| % Institutions | 3.48% |
Historical Volatility
HV 10-Day
30.73%
HV 20-Day
56.98%
HV 30-Day
60.91%
HV 60-Day
59.52%
HV Rank
43.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($35.00 target)
2
Strong Buy1
BuyData last updated: 4/29/2026